Professor, Medicine - Oncology, Stanford University Medical Center
Oncology
Dr. Dean Felsher, MD
|
|
Give Review
Dean Felsher is an expert in the field of Oncology. He went to David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a one of the best medicals schools. David Geffen School of Medicine at UCLA has a rank of 13 in research and a 7 in primary care He over the years received 1 awards: "Elected Member". Dr. Dean Felsher has written publications. He has 23 publications published with PubMed. The lastest publication is: 'MYC regulates the antitumor immune response through CD47 and PD-L1.'
Publications
- Designing a broad-spectrum integrative approach for Cancer prevention and treatment.
- p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.
- Inactivation of MYC reverses tumorigenesis.
- Alteration of the lipid profile in Lymphomas induced by MYC overexpression.
- Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo.
- An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.
- Cancer therapy: development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined Cancer magnetic resonan...
- BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
- A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide.
- Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and T...
- Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of Cancer.
- Noncanonical roles of the immune system in eliciting oncogene addiction.
- Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling.
- Role of MYCN in retinoblastoma.
- CD271+ Bone Marrow Mesenchymal Stem Cells May Provide a Niche for Dormant Mycobacterium tuberculosis.
- Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
- Activation of cre recombinase alone can induce complete tumor regression.
- MYC Activation Is a Hallmark of Cancer Initiation and Maintenance.
- Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
- In Vivo Imaging-Based Mathematical Modeling Techniques That Enhance the Understanding of Oncogene Addiction in relation to Tumor Growth.
- MYC regulates the antitumor immune response through CD47 and PD-L1.
- Metabolic vulnerabilities of MYC-induced Cancer.
Schools
David Geffen School Of Medicine At UCLA University Of California Los Angeles
Hospital Of The University Of Pennsylvania
University Calif San Francisco
Conditions Treated
- Lymphoma
- Neutropenia
- Non-Hodgkin's Lymphoma
- Pancreatic Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
UCSF -
University of Pennsylvania Health System -
David Geffen School of Medicine at UCLA
Hospital
-
Stanford Health Care
Helpful Reviews
Similar Doctors
|
|
Dr. Joseph A. Mollick, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allyson C. Spence, MD |
|
|
Dr. Rajat Rohatgi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren S. Maeda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ginna G. Laport, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Oyebimpe O. Adesina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael F. Clarke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Y. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold N. Keer, MD
This Doctor is OpenDoctor Recommended.
|